307 related articles for article (PubMed ID: 29210644)
1. Carboxylesterase Inhibitors: An Update.
Zou LW; Jin Q; Wang DD; Qian QK; Hao DC; Ge GB; Yang L
Curr Med Chem; 2018; 25(14):1627-1649. PubMed ID: 29210644
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the discovery of natural inhibitors against human carboxylesterases.
Wang DD; Zou LW; Jin Q; Hou J; Ge GB; Yang L
Fitoterapia; 2017 Mar; 117():84-95. PubMed ID: 28126414
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the inhibition of human carboxylesterases (CESs) by the active ingredients from
Fu Q; Yang K; Hu RX; Du Z; Hu CM; Zhang X
Xenobiotica; 2019 Nov; 49(11):1260-1268. PubMed ID: 30486721
[TBL] [Abstract][Full Text] [Related]
4. Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung.
Gabriele M; Puccini P; Lucchi M; Vizziello A; Gervasi PG; Longo V
Biochem Pharmacol; 2018 Apr; 150():64-71. PubMed ID: 29407485
[TBL] [Abstract][Full Text] [Related]
5. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase.
Shimizu M; Fukami T; Nakajima M; Yokoi T
Drug Metab Dispos; 2014 Jul; 42(7):1103-9. PubMed ID: 24751575
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of carboxylesterase activity of THP1 monocytes/macrophages and recombinant human carboxylesterase 1 by oxysterols and fatty acids.
Crow JA; Herring KL; Xie S; Borazjani A; Potter PM; Ross MK
Biochim Biophys Acta; 2010 Jan; 1801(1):31-41. PubMed ID: 19761868
[TBL] [Abstract][Full Text] [Related]
7. Human carboxylesterases: a comprehensive review.
Wang D; Zou L; Jin Q; Hou J; Ge G; Yang L
Acta Pharm Sin B; 2018 Sep; 8(5):699-712. PubMed ID: 30245959
[TBL] [Abstract][Full Text] [Related]
8. Effects of alcohol on human carboxylesterase drug metabolism.
Parker RB; Hu ZY; Meibohm B; Laizure SC
Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos oxon, paraoxon and methyl paraoxon.
Crow JA; Bittles V; Herring KL; Borazjani A; Potter PM; Ross MK
Toxicol Appl Pharmacol; 2012 Jan; 258(1):145-50. PubMed ID: 22100607
[TBL] [Abstract][Full Text] [Related]
10. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.
Wong CC; Cheng KW; Xie G; Zhou D; Zhu CH; Constantinides PP; Rigas B
J Pharmacol Exp Ther; 2012 Feb; 340(2):422-32. PubMed ID: 22085648
[TBL] [Abstract][Full Text] [Related]
11. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2.
Wang J; Williams ET; Bourgea J; Wong YN; Patten CJ
Drug Metab Dispos; 2011 Aug; 39(8):1329-33. PubMed ID: 21540359
[TBL] [Abstract][Full Text] [Related]
12. Identification of carboxylesterases expressed in rat intestine and effects of their hydrolyzing activity in predicting first-pass metabolism of ester prodrugs.
Liu D; Gao J; Zhang C; Ren X; Liu Y; Xu Y
Pharmazie; 2011 Nov; 66(11):888-93. PubMed ID: 22204136
[TBL] [Abstract][Full Text] [Related]
13. Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597.
Crow JA; Bittles V; Borazjani A; Potter PM; Ross MK
Biochem Pharmacol; 2012 Nov; 84(9):1215-22. PubMed ID: 22943979
[TBL] [Abstract][Full Text] [Related]
14. Discovery of natural pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1.
Song PF; Zhu YD; Ma HY; Wang YN; Wang DD; Zou LW; Ge GB; Yang L
Fitoterapia; 2019 Sep; 137():104199. PubMed ID: 31175950
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrazolones as novel carboxylesterase 2 inhibitors that potently inhibit the adipogenesis in cells.
Qian XK; Zhang J; Song PF; Zhao YS; Ma HY; Jin Q; Wang DD; Guan XQ; Li SY; Bao X; Zou LW
Bioorg Med Chem; 2021 Jun; 40():116187. PubMed ID: 33965840
[TBL] [Abstract][Full Text] [Related]
16. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
17. Potential Pharmacokinetic Herb-Drug Interactions: Have we Overlooked the Importance of Human Carboxylesterases 1 and 2?
Xu J; Qiu JC; Ji X; Guo HL; Wang X; Zhang B; Wang T; Chen F
Curr Drug Metab; 2019; 20(2):130-137. PubMed ID: 29600756
[TBL] [Abstract][Full Text] [Related]
18. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Merali Z; Ross S; Paré G
Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation Capacity of Carboxylesterase in Skin and Keratinocytes for the Penta-Ethyl Ester Prodrug of DTPA.
Fu J; Sadgrove M; Marson L; Jay M
Drug Metab Dispos; 2016 Aug; 44(8):1313-8. PubMed ID: 27130352
[TBL] [Abstract][Full Text] [Related]
20. Per- and polyfluoroalkyl substances exert strong inhibition towards human carboxylesterases.
Liu YZ; Pan LH; Bai Y; Yang K; Dong PP; Fang ZZ
Environ Pollut; 2020 Aug; 263(Pt A):114463. PubMed ID: 32283456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
